Pharma BD Deal Intelligence
On October 13, 2026 Alaunos Therapeutics, Inc. (Nasdaq: TCRT) announced the completed acquisition of privately held Velaris Therapeutics, Inc., bringing in a portfolio of ActRII-Fc ligand traps and complementary biologics aimed at the signalling imbalances that drive pulmonary vascular remodelling. The acquisition consideration was not disclosed. Concurrently Alaunos raised approximately $350 million in gross proceeds through a private placement of Series C non-voting convertible preferred stock led by Fairmount, with participation from Venrock Healthcare Capital Partners and other accounts; the financing is expected to fund operations into 2029, supporting multiple data milestones including clinical proof-of-concept for VLR199 in 2028. Structurally this follows the listed-shell-plus-PIPE pattern - a former TCR-therapy company repurposed around an acquired cardiopulmonary pipeline - but the primary filing describes it as an acquisition by Alaunos, which is how it is recorded here.
← Browse all deals · How we score deals
More: 2026 deals